PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae918 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Patricia Vaduva und 22 weiteren Autor:innen. Beteiligte Einrichtung: Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Paris 75014, France. Hauptthemen laut MEDLINE: Phosphoric Diester Hydrolases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fondation pour la Recherche Médicale, French Society of Endocrinology, IPSEN.
Abstract (Originalsprache)
Context
Primary bilateral macronodular adrenal hyperplasia (PBMAH), the most common cause of Cushing syndrome due to bilateral nodules, is a heterogeneous disease at the clinical, hormonal, and morphological levels. ARMC5-inactivating pathogenic variants are causative of PBMAH, and rare variants of PDE11A have been associated with PBMAH.
Objective
The aim of this study, on a large cohort of individuals with PBMAH from Europe and America, was to study the ARMC5 and PDE11A genotype to determine the genotype/phenotype correlation and to investigate the hypothesis that PDE11A could be a modifying gene of the adrenal phenotype.
Methods
Leukocyte DNA of 354 PBMAH index cases was sequenced for ARMC5 and PDE11A genes by next-generation sequencing. Phenotypic characteristics of 334 of these patients were analyzed to study the genotype/phenotype correlations.
Results
Seven out of 16 PDE11A variants were considered damaging according to in silico predictions: 6 missense variants (p.Tyr727Cys, p.Met623Arg, p.Tyr658Cys, p.Ag867Trp, p.Asn298Ser, p.Glu840Lys) and 1 stop-gain variant (p.Arg307Ter). In the cohort, 11.4% of patients had one of these variants and 19.2% had ARMC5-pathogenic variants. There was no statistically significant difference in the distribution of PDE11A-damaging variants according to ARMC5 status (P = .83; OR = 0.79; 95% CI, 0.26-2.03) nor in the distribution of ARMC5 pathogenic variants according to PDE11A status (P = .83; OR = 0.81; 95% CI, 0.27-2.04). Patients with PDE11A-damaging variants had lower urinary free cortisol (0.7 vs 1.25 upper limit of normal; P = .0002), midnight plasma cortisol (157.81 vs 222.19 nmol/L, P = .016), and number of adrenal nodules (3.46 vs 4.74; P = .048) compared to PDE11A wild-type patients. Patients with ARMC5-pathogenic variants had a more severe phenotype with more frequent comorbidities and were more often treated by adrenalectomy (60%).
Conclusion
PDE11A appears to be a modulator of PBMAH phenotype, damaging variants being associated with an attenuated form. This may contribute to the heterogeneity of PBMAH and could affect patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Paris 75014, France.
- Department of Endocrinology, Reference Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris 75014, France.
- Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, Lille 59000, France.
- Department of Genomic Medicine of Tumors and Cancers, Cochin Hospital, APHP, Paris 75014, France.
- Department of Endocrinology, Adrenal Unit, University of Sao Paulo, São Paulo 03178-200, Brazil.
- Department of Internal Medicine IV, LMU University Hospital and Ludwig-Maximilians-Universität München, Munich 80539, Germany.
ORCID-Profile: Patricia Vaduva, Lucas Bouys, Annabel Berthon, Florian Violon, Gerald Raverot, Helene Lasolle, Antoine Tabarin, Peter Kamenicky, Eric Pasmant, Jérôme Bertherat
Förderung
- Fondation pour la Recherche Médicale
- French Society of Endocrinology
- IPSEN
- National Institutes of Health
Zitieren
APA
Vaduva, P., Bouys, L., Jouinot, A., Espiard, S., Chansavang, A., Berthon, A., Néou, M., Vaczlavik, A., Violon, F., Charchar, H., Kroiss, M., Raverot, G., Lasolle, H., Guignat, L., Libé, R., Assié, G., Tabarin, A., Kamenicky, P., Pasmant, E., …, & Bertherat, J. (2025). PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae918
Vancouver
Vaduva P, Bouys L, Jouinot A, Espiard S, Chansavang A, Berthon A, et al. PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae918
BibTeX
@article{Vaduva2025,
author = {Vaduva, Patricia and Bouys, Lucas and Jouinot, Anne and Espiard, Stephanie and Chansavang, Albain and Berthon, Annabel and Néou, Mario and Vaczlavik, Anna and Violon, Florian and Charchar, Helaine and Kroiss, Matthias and Raverot, Gerald and Lasolle, Helene and Guignat, Laurence and Libé, Rossella and Assié, Guillaume and Tabarin, Antoine and Kamenicky, Peter and Pasmant, Eric and Fragoso, Maria and Stratakis, Constantine and Ragazzon, Bruno and Bertherat, Jérôme},
title = {PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae918}
}
EUVIMED